NeoGenomics announced new data highlighting its RaDaR assay for minimal residual disease will be presented at the 46th annual San Antonio Breast Cancer Symposium. RaDaR data will be presented during a Poster Spotlight Session featuring an updated analysis of the TRACER study, which assessed patients with early-stage breast cancer across multiple subtypes and the potential utility of using RaDaR in this setting, including for baseline detection, for monitoring therapy response in the neoadjuvant setting, and for post-operative recurrence monitoring. “The TRACER data continues to demonstrate the value of RaDaR technology, especially in excellent baseline detection of circulating tumor DNA to facilitate therapy response monitoring before and during neoadjuvant therapy,” said Vishal Sikri, President of Advanced Diagnostics at NeoGenomics. “Evaluating therapy response is essential to cancer care, enabling patients and their physicians to make more informed treatment decisions that may improve cancer outcomes.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NEO:
- NeoGenomics price target raised to $16 from $15 at BofA
- NeoGenomics price target lowered to $22 from $23 at TD Cowen
- NEO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- NeoGenomics price target lowered to $16 from $18 at Morgan Stanley
- NeoGenomics announces commercial availability of two new tests